Insight Molecular Diagnostics Debt to Equity Ratio 2014-2025 | IMDX
Current and historical debt to equity ratio values for Insight Molecular Diagnostics (IMDX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Insight Molecular Diagnostics debt/equity for the three months ending September 30, 2025 was 0.00.
| Insight Molecular Diagnostics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-09-30 | $0.05B | $-0.01B | -5.78 |
| 2025-06-30 | $0.05B | $0.00B | 45.01 |
| 2025-03-31 | $0.05B | $0.01B | 4.91 |
| 2024-12-31 | $0.05B | $-0.01B | -3.86 |
| 2024-09-30 | $0.06B | $0.01B | 6.23 |
| 2024-06-30 | $0.05B | $0.02B | 2.29 |
| 2024-03-31 | $0.06B | $0.01B | 5.13 |
| 2023-12-31 | $0.05B | $0.02B | 2.66 |
| 2023-09-30 | $0.04B | $0.04B | 1.17 |
| 2023-06-30 | $0.04B | $0.04B | 1.01 |
| 2023-03-31 | $0.05B | $0.04B | 1.18 |
| 2022-12-31 | $0.07B | $0.03B | 1.92 |
| 2022-09-30 | $0.08B | $0.08B | 1.05 |
| 2022-06-30 | $0.09B | $0.08B | 1.06 |
| 2022-03-31 | $0.09B | $0.06B | 1.57 |
| 2021-12-31 | $0.09B | $0.07B | 1.45 |
| 2021-09-30 | $0.07B | $0.10B | 0.69 |
| 2021-06-30 | $0.08B | $0.10B | 0.73 |
| 2021-03-31 | $0.02B | $0.11B | 0.21 |
| 2020-12-31 | $0.02B | $0.03B | 0.66 |
| 2020-09-30 | $0.02B | $0.04B | 0.67 |
| 2020-06-30 | $0.02B | $0.04B | 0.60 |
| 2020-03-31 | $0.02B | $0.04B | 0.63 |
| 2019-12-31 | $0.01B | $0.03B | 0.29 |
| 2019-09-30 | $0.00B | $0.03B | 0.12 |
| 2019-06-30 | $0.00B | $0.03B | 0.12 |
| 2019-03-31 | $0.00B | $0.04B | 0.09 |
| 2018-12-31 | $0.01B | $0.00B | 1.78 |
| 2018-09-30 | $0.01B | $0.01B | 0.72 |
| 2018-06-30 | $0.01B | $0.01B | 0.78 |
| 2018-03-31 | $0.01B | $0.01B | 0.73 |
| 2017-12-31 | $0.01B | $0.00B | 1.32 |
| 2017-09-30 | $0.01B | $0.01B | 0.77 |
| 2017-06-30 | $0.01B | $0.01B | 1.15 |
| 2017-03-31 | $0.01B | $0.01B | 0.73 |
| 2016-12-31 | $0.01B | $0.01B | 0.47 |
| 2016-09-30 | $0.00B | $0.01B | 0.33 |
| 2016-06-30 | $0.00B | $0.00B | 0.66 |
| 2016-03-31 | $0.00B | $0.01B | 0.40 |
| 2015-12-31 | $0.00B | $0.01B | 0.22 |
| 2015-09-30 | $0.00B | $0.00B | 0.00 |
| 2015-06-30 | $0.00B | $0.00B | 0.00 |
| 2015-03-31 | $0.00B | $0.00B | 0.00 |
| 2014-12-31 | $0.01B | $0.00B | -5.90 |
| 2013-12-31 | $0.01B | $0.00B | 1.29 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.190B | $0.002B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $36.527B | 42.25 |
| Tempus AI (TEM) | United States | $12.512B | 0.00 |
| Doximity (DOCS) | United States | $7.768B | 31.98 |
| Hims & Hers Health (HIMS) | United States | $7.144B | 58.11 |
| IRHYTHM HLDGS (IRTC) | United States | $5.386B | 0.00 |
| Hinge Health (HNGE) | United States | $3.411B | 0.00 |
| Heartflow (HTFL) | United States | $3.165B | 0.00 |
| Privia Health (PRVA) | United States | $2.868B | 179.38 |
| Inspire Medical Systems (INSP) | United States | $2.680B | 44.34 |
| 10x Genomics (TXG) | United States | $2.597B | 0.00 |
| Omnicell (OMCL) | United States | $2.267B | 46.35 |
| Azenta (AZTA) | United States | $1.840B | 75.47 |
| Enovis (ENOV) | United States | $1.371B | 7.20 |
| Clover Health Investments (CLOV) | United States | $1.312B | 0.00 |
| Schrodinger (SDGR) | United States | $1.237B | 0.00 |
| Butterfly Network (BFLY) | United States | $1.051B | 0.00 |
| Phreesia (PHR) | United States | $0.988B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.868B | 0.00 |
| Talkspace (TALK) | United States | $0.656B | 132.00 |
| Standard BioTools (LAB) | United States | $0.600B | 0.00 |
| Claritev (CTEV) | United States | $0.503B | 0.00 |
| Evolent Health (EVH) | United States | $0.421B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.368B | 0.00 |
| Carlsmed (CARL) | United States | $0.334B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.334B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.317B | 0.00 |
| TruBridge (TBRG) | United States | $0.311B | 14.28 |
| CapsoVision (CV) | United States | $0.292B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.255B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.182B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.171B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.163B | 0.00 |
| CareCloud (CCLD) | United States | $0.123B | 6.74 |
| Outset Medical (OM) | United States | $0.096B | 0.00 |
| American Well (AMWL) | United States | $0.077B | 0.00 |
| Pulmonx (LUNG) | United States | $0.073B | 0.00 |
| HeartBeam (BEAT) | United States | $0.072B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.070B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.067B | 0.00 |
| 111 (YI) | China | $0.049B | 0.00 |
| Precipio (PRPO) | United States | $0.041B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.038B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.023B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.022B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| Zhongchao (ZCMD) | China | $0.013B | 0.00 |
| HeartSciences (HSCS) | United States | $0.010B | 0.00 |
| PROFUSA (PFSA) | United States | $0.009B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.008B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Movano (MOVE) | United States | $0.006B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |